PeptideForge
BuilderBuild a peptide residue by residue — live chemistry, challenges, and XP.
Design Lab
BetaSequence properties — pI, ε280, net charge, and synthesis-difficulty flags.
Featured monographs
Verified reference entries — reviewed, sourced, and cross-checked against known chemistry.
Semaglutide
aka Ozempic, Wegovy, Rybelsus
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
Tirzepatide
aka Mounjaro, Zepbound
Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
Retatrutide
aka LY3437943, Triple G, GGG agonist, GIP/GLP-1/glucagon triple agonist
Investigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.
BPC-157
aka Body Protective Compound 157, PL 14736
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
Tesamorelin
aka Egrifta
GHRH analog FDA-approved for HIV-associated lipodystrophy.
Cagrilintide
Long-acting amylin analog — Novo Nordisk’s answer to GLP-1 from a second satiety pathway, studied alone and as half of CagriSema. Phase 3 monotherapy reported ~11.8% mean weight loss.
Ipamorelin
Selective ghrelin receptor agonist (GHRP) with minimal cortisol / prolactin release.
MOTS-c
Mitochondrially-encoded peptide with reported insulin-sensitizing activity.
Every compound, by category
The complete verified index — 88 entries across 11 research categories.
Search any compound in PubChem
For anything not yet in our reference, look it up directly in PubChem — the NIH open chemistry database — and pull its structure, molecular formula, and weight.
Data source: PubChem (NIH National Library of Medicine)
For research and educational reference only. Entries describe the scientific literature and are not medical advice, dosing guidance, or an offer to sell any compound.